Side Effects of Dexamethasone
Dexamethasone carries significant dose-dependent and duration-dependent adverse effects, with serious complications occurring in 11-14% of patients on high-dose therapy, including severe psychoses, gastrointestinal ulcers requiring surgery, hemorrhage, and perforations. 1
Short-Term Adverse Effects (Within Days to Weeks)
Common Side Effects
The most frequently reported short-term adverse effects include:
- Insomnia (31-45% of patients) - most common complaint 2, 3
- Gastrointestinal effects: Dyspepsia/epigastric discomfort (21-27%), increased appetite (19%) 3
- Neuropsychiatric symptoms: Agitation (27%), severe psychoses (in high-dose therapy) 1, 3
- Metabolic effects: Hyperglycemia, particularly pronounced in diabetic patients 4
- Weight gain (16-47 pounds in pregnant women on prolonged therapy) 3, 5
- Hiccups, flushing, and increased radicular pain (when used for epidural injections) 6
Serious Short-Term Complications
High-dose dexamethasone (≥96 mg/day) carries an 11% risk of serious toxicity 1, including:
- Gastric ulcers requiring surgery
- Gastrointestinal hemorrhage and perforations
- Rectal bleeding
- Severe psychoses 1, 7
Critical distinction: The FDA label warns of serious neurologic events including spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke when dexamethasone is used epidurally 8.
Long-Term Adverse Effects (Weeks to Months)
Dose-Dependent Toxicity Pattern
A clear dose-response relationship exists: patients with the greatest dexamethasone exposure (mean 243 mg over 27 days) experienced Grade 3+ adverse events in 65% of cases versus 15% in unexposed patients (OR 15.1,95% CI 1.4-160.8) 9.
Specific Long-Term Effects
Endocrine/Metabolic:
- Hyperglycemia: Mild increase in non-diabetics (13 mg/dL increase within 12 hours) 4
- More pronounced in diabetics (32 mg/dL increase) 4
- Adrenal suppression requiring stress-dose coverage 8
- Cushingoid features with prolonged use 5
Musculoskeletal:
Dermatologic:
Ophthalmologic:
Infectious:
- Increased infection risk (17% in cancer patients) 9
- Decreased resistance and inability to localize infections 8
- Reactivation of latent infections (amebiasis) 8
Cardiovascular:
Special Population: Neonates
Critical neurodevelopmental concerns: High-dose dexamethasone (≥0.5 mg/kg/day) in neonates causes:
- Neurodevelopmental impairment 11
- Decreased hippocampal volume 11
- Altered hippocampal synaptic plasticity and memory formation 11
- Degeneration and necrosis of hippocampal neurons (animal models) 11
This contrasts with hydrocortisone, which shows no such effects, likely due to dexamethasone's selective glucocorticoid receptor binding versus hydrocortisone's dual mineralocorticoid/glucocorticoid receptor activity 11.
Monitoring Strategy
Baseline Assessment
Before initiating dexamethasone, evaluate for contraindications 10:
- Diabetes or glucose intolerance
- Cardiovascular disease
- Peptic ulcer disease
- Recurrent infections or immunosuppression
- Glaucoma risk factors
- Osteoporosis risk
Active Monitoring Protocol 10
Monitor for:
- Glucose levels: Particularly in diabetics and during first 24 hours
- Blood pressure: Regular monitoring for hypertension
- Weight: Track for excessive gain
- Infections: Heightened surveillance
- Neuropsychological changes: Mood, sleep, psychosis
- Gastrointestinal symptoms: Epigastric pain, bleeding
- Ophthalmologic screening: For cataracts and glaucoma with prolonged use
Management Strategies
Dose Optimization
Use the minimum effective dose 1:
- Standard dose: ≤6 mg/day for most indications (used in 80% of COVID-19 hospitalizations) 12
- High-dose therapy (>10 mg/day): Reserve only for specific indications (spinal cord compression, cerebral edema) where benefits clearly outweigh risks 1, 7, 8
- Avoid prolonged high-dose therapy: Serious adverse effects increase from 0% with moderate doses to 14% with high doses 1
Duration Minimization
- Limit treatment to <14 days when possible 13
- Rapid taper: Can be accomplished in 2-3 days for most patients after short courses 13
- Avoid abrupt discontinuation after prolonged use (>few days) to prevent adrenal insufficiency 8
Prophylactic Measures
Osteoporosis prevention 10:
- Calcium and vitamin D supplementation
- Bisphosphonates for high-risk patients
- Weight-bearing exercise
Gastrointestinal protection:
- PPI co-prescription shows no significant benefit in reducing GI side effects 13
- Use selectively based on individual risk factors rather than routinely
Infection prevention:
- Avoid live vaccines during immunosuppressive therapy 8
- Screen for latent infections (tuberculosis, amebiasis) before prolonged therapy 8
- Counsel patients on infection risk, particularly chickenpox and measles exposure 8
Glucose management:
- More intensive monitoring in diabetics
- Adjust antihyperglycemic medications proactively 4
Stress-Dose Coverage
Patients on prolonged dexamethasone require increased dosing during physiologic stress (surgery, infection, trauma) due to HPA axis suppression 8. Consider mineralocorticoid supplementation as dexamethasone lacks sodium-retaining properties 8.
Common Pitfalls to Avoid
Prescribing high doses (>10 mg/day) without clear indication: Over 20% of COVID-19 patients requiring minimal oxygen received inappropriately high doses 12
Prolonging therapy unnecessarily: Each additional week increases adverse event risk substantially 9
Routine PPI co-prescription: Not evidence-based and adds unnecessary medication burden 13
Inadequate patient counseling: Patients must understand expected side effects (insomnia, mood changes, increased appetite) to maintain compliance and report serious symptoms early 10
Abrupt discontinuation: After >few days of treatment, taper gradually to avoid adrenal crisis 8
Ignoring drug interactions: Particularly with amphotericin B (cardiac complications) and NSAIDs (increased GI perforation risk in neonates) 11, 8